U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06975371) titled 'Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i' on May 09.
Brief Summary: This study aims to assess the treatment patterns and real-world outcomes of HR+/HER- metastatic breast cancer patients who have progressed on 1L ET + CDK4/6i and started a second line (2L) treatment within a real-world cohort in the United States Flatiron Health Database.
Study Start Date: April 14
Study Type: OBSERVATIONAL
Condition:
Advanced/Metastatic HER2-negative Breast Cancer
Intervention:
OTHER: No drug
No study drug was administered in this non-interventional study.
Recruitment Status: RE...